Last updated: 23 May 2024 at 4:55pm EST

Thomas Loewald Net Worth




The estimated Net Worth of Thomas W Loewald is at least 7.86 百万$ dollars as of 20 August 2019. Mr. Loewald owns over 20,000 units of Harvard Bioscience stock worth over 292,056$ and over the last 13 years he sold HBIO stock worth over 7,431,483$. In addition, he makes 136,501$ as Independent Director at Harvard Bioscience.

Mr. Loewald HBIO stock SEC Form 4 insiders trading

Thomas has made over 24 trades of the Harvard Bioscience stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of HBIO stock worth 50,600$ on 20 August 2019.

The largest trade he's ever made was exercising 22,437 units of Harvard Bioscience stock on 6 February 2014 worth over 1,110,407$. On average, Thomas trades about 2,903 units every 39 days since 2012. As of 20 August 2019 he still owns at least 103,200 units of Harvard Bioscience stock.

You can see the complete history of Mr. Loewald stock trades at the bottom of the page.





Thomas Loewald biography

Thomas W. Loewald serves as Independent Director of the Company. Mr. Loewald has served as President of the Flexible Packaging Division of ProAmpac, a private-equity owned flexible packaging company. Prior to that, he served as Senior Vice President and Chief Commercial Officer of Thermo Fisher Scientific, a multinational biotechnology product development company. He previously worked in various roles of Thermo Fisher Scientific from 2002 to 2016. Prior to Thermo Fisher, Mr. Loewald led sales, marketing, and customer service for the adhesives division of Tyco International from 1998 to 2002. Prior to Tyco, Tom held a series of roles with General Electric’s Plastics and Materials businesses. Mr. Loewald holds a B.A. in economics from Middlebury College and an M.B.A. in business administration from Dartmouth College.

What is the salary of Thomas Loewald?

As the Independent Director of Harvard Bioscience, the total compensation of Thomas Loewald at Harvard Bioscience is 136,501$. There are 8 executives at Harvard Bioscience getting paid more, with James Green having the highest compensation of 2,422,600$.



How old is Thomas Loewald?

Thomas Loewald is 57, he's been the Independent Director of Harvard Bioscience since 2017. There are 6 older and 5 younger executives at Harvard Bioscience. The oldest executive at Harvard Bioscience Inc. is John Kennedy, 71, who is the Independent Director.

What's Thomas Loewald's mailing address?

Thomas's mailing address filed with the SEC is C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL RD., HOLLISTON, MA, 01746.

Insiders trading at Harvard Bioscience

Over the last 21 years, insiders at Harvard Bioscience have traded over 10,145,146$ worth of Harvard Bioscience stock and bought 754,658 units worth 2,380,232$ . The most active insiders traders include Earl R LewisBertrand LoyDavid Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of 182,054$. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth 29,100$.



What does Harvard Bioscience do?

harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.



What does Harvard Bioscience's logo look like?

Harvard Bioscience Inc. logo

Complete history of Mr. Loewald stock trades at Harvard Bioscience、Thermo Fisher Scientific

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
20 Aug 2019 Thomas W Loewald
ディレクター
購入する 20,000 2.53$ 50,600$
20 Aug 2019
103,200
27 Apr 2017 Thomas W Loewald
上席副社長
販売 1,532 168.76$ 258,540$
27 Apr 2017
41,277
8 Mar 2017 Thomas W Loewald
上席副社長
オプション行使 7,675 73.24$ 562,117$
8 Mar 2017
50,484
8 Mar 2017 Thomas W Loewald
上席副社長
オプション行使 7,675 73.24$ 562,117$
8 Mar 2017
50,484
6 Mar 2017 Thomas W Loewald
上席副社長
販売 4,049 158.71$ 642,617$
6 Mar 2017
42,809
6 Mar 2017 Thomas W Loewald
上席副社長
販売 4,049 158.71$ 642,617$
6 Mar 2017
42,809
29 Aug 2016 Thomas W Loewald
上席副社長
販売 3,256 152.28$ 495,824$
29 Aug 2016
35,814
29 Aug 2016 Thomas W Loewald
上席副社長
販売 3,256 152.28$ 495,824$
29 Aug 2016
35,814
26 Aug 2016 Thomas W Loewald
上席副社長
販売 913 151.92$ 138,703$
26 Aug 2016
39,070
13 Jul 2016 Thomas W Loewald
上席副社長
オプション行使 8,025 73.24$ 587,751$
13 Jul 2016
52,194
2 Jun 2016 Thomas W Loewald
上席副社長
オプション行使 15,000 73.24$ 1,098,600$
2 Jun 2016
59,169
3 Mar 2016 Thomas W Loewald
上席副社長
オプション行使 3,625 49.49$ 179,401$
3 Mar 2016
47,794
14 Dec 2015 Thomas W Loewald
上席副社長
販売 13,013 134.18$ 1,746,084$
14 Dec 2015
31,438
30 Mar 2015 Thomas W Loewald
上席副社長
販売 5,307 134.40$ 713,261$
30 Mar 2015
40,663
20 Feb 2015 Thomas W Loewald
上席副社長
オプション行使 15,037 54.97$ 826,584$
20 Feb 2015
51,899
26 Aug 2014 Thomas W Loewald
上席副社長
販売 2,349 120.90$ 283,994$
26 Aug 2014
36,862
25 Jul 2014 Thomas W Loewald
上席副社長
オプション行使 6,000 54.97$ 329,820$
25 Jul 2014
47,307
28 Apr 2014 Thomas W Loewald
上席副社長
オプション行使 8,688 49.49$ 429,969$
28 Apr 2014
49,995
10 Mar 2014 Thomas W Loewald
上席副社長
販売 5,241 125.90$ 659,842$
10 Mar 2014
41,307
6 Feb 2014 Thomas W Loewald
上席副社長
オプション行使 22,437 49.49$ 1,110,407$
6 Feb 2014
64,420
2 Mar 2013 Thomas W Loewald
上席副社長
販売 4,761 74.57$ 355,028$
2 Mar 2013
43,646
25 Feb 2013 Thomas W Loewald
上席副社長
販売 1,756 73.29$ 128,697$
25 Feb 2013
28,603
13 Nov 2012 Thomas W Loewald
上席副社長
オプション行使 21,600 36.10$ 779,760$
13 Nov 2012
53,336
19 Mar 2012 Thomas W Loewald
上席副社長
販売 15,078 57.73$ 870,453$
19 Mar 2012
31,736


Harvard Bioscience executives and stock owners

Harvard Bioscience executives and other stock owners filed with the SEC include: